Citations (33)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Long Meng, Yun Fang, Yongfei Chen, Huaijun Zhu & Rui Long. (2015) High versus low vancomycin serum trough regimen for Gram-positive infections: a meta-analysis. Journal of Chemotherapy 27:4, pages 213-220.
Read now
Read now
Nisha P. Shah, Prabashni Reddy, Joseph A. Paladino, Peggy S. McKinnon, Michael E. Klepser & Chris L. Pashos. (2004) Direct medical costs associated with using vancomycin in methicillin-resistant Staphylococcus aureus infections: an economic model. Current Medical Research and Opinion 20:6, pages 779-790.
Read now
Read now
Articles from other publishers (31)
Kimberly M. Brothers, Dana M. Parker, Masashi Taguchi, Dongzhu Ma, Jonathan B. Mandell, Lance L. Thurlow, Venkata C. Byrapogu & Kenneth L. Urish. (2023) Dose optimization in surgical prophylaxis: sub-inhibitory dosing of vancomycin increases rates of biofilm formation and the rates of surgical site infection. Scientific Reports 13:1.
Crossref
Crossref
Yulin Wang, Jian Yang, Haiyan Zhan, Shuxiao Zhang & Yin Deng. (2021) The potential risk factors of nephrotoxicity during vancomycin therapy in Chinese adult patients. European Journal of Hospital Pharmacy 28:e1, pages e51-e55.
Crossref
Crossref
Ioannis Bellos, Georgios Daskalakis & Vasilios Pergialiotis. (2020) Relationship of vancomycin trough levels with acute kidney injury risk: an exposure–toxicity meta-analysis. Journal of Antimicrobial Chemotherapy 75:10, pages 2725-2734.
Crossref
Crossref
Michael J Rybak, Jennifer Le, Thomas P Lodise, Donald P Levine, John S Bradley, Catherine Liu, Bruce A Mueller, Manjunath P Pai, Annie Wong-Beringer, John C Rotschafer, Keith A Rodvold, Holly D Maples & Benjamin M Lomaestro. (2020)
Therapeutic monitoring of vancomycin for serious methicillin-resistant
Staphylococcus aureus
infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists
. American Journal of Health-System Pharmacy 77:11, pages 835-864.
Crossref
Crossref
R. Brigg Turner, Kyle Kojiro, Emily A. Shephard, Regina Won, Eric Chang, Dominic Chan & Fawzy Elbarbry. (2018) Review and Validation of Bayesian Dose‐Optimizing Software and Equations for Calculation of the Vancomycin Area Under the Curve in Critically Ill Patients. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 38:12, pages 1174-1183.
Crossref
Crossref
Amy D. Robertson, Chenghui Li, Drayton A. Hammond & Tiffany A. Dickey. (2018) Incidence of Acute Kidney Injury Among Patients Receiving the Combination of Vancomycin with Piperacillin‐Tazobactam or Meropenem. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 38:12, pages 1184-1193.
Crossref
Crossref
Cory M. Hale, Robert W. Seabury, Jeffrey M. Steele, William Darko & Christopher D. Miller. (2016) Are Vancomycin Trough Concentrations of 15 to 20 mg/L Associated With Increased Attainment of an AUC/MIC ≥ 400 in Patients With Presumed MRSA Infection?. Journal of Pharmacy Practice 30:3, pages 329-335.
Crossref
Crossref
Sasima Tongsai & Pornpan Koomanachai. (2016) The safety and efficacy of high versus low vancomycin trough levels in the treatment of patients with infections caused by methicillin-resistant Staphylococcus aureus: a meta-analysis. BMC Research Notes 9:1.
Crossref
Crossref
Drayton A. Hammond, Melanie N. Smith, Jacob T. Painter, Nikhil K. Meena & Katherine Lusardi. (2016) Comparative Incidence of Acute Kidney Injury in Critically Ill Patients Receiving Vancomycin with Concomitant Piperacillin-Tazobactam or Cefepime: A Retrospective Cohort Study. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 36:5, pages 463-471.
Crossref
Crossref
Jennifer Le, Pamela Ny, Edmund Capparelli, James Lane, Becky Ngu, Richard Muus, Gale Romanowski, Tiana Vo & John Bradley. (2015) Pharmacodynamic Characteristics of Nephrotoxicity Associated With Vancomycin Use in Children. Journal of the Pediatric Infectious Diseases Society 4:4, pages e109-e116.
Crossref
Crossref
Yan Liu, You Yin, Xin-Zhu Liu, Hui-Juan Yao, Li-Xia Li, Ji-Hui Chen, Ting Chen, Xiao-Tong Lu, Shu-Hong Bu & Jian Zhang. (2015) Retrospective Analysis of Vancomycin Nephrotoxicity in Elderly Chinese Patients. Pharmacology 95:5-6, pages 279-284.
Crossref
Crossref
Jackson Kim, Shane M. Burke, Evan Qu, Steven W. Hwang & Ron I. Riesenburger. (2015) Application of Intrawound Vancomycin Powder during Spine Surgery in a Patient with Dialysis-Dependent Renal Failure. Case Reports in Surgery 2015, pages 1-5.
Crossref
Crossref
Manjunath P. Pai, Michael Neely, Keith A. Rodvold & Thomas P. Lodise. (2014) Innovative approaches to optimizing the delivery of vancomycin in individual patients. Advanced Drug Delivery Reviews 77, pages 50-57.
Crossref
Crossref
Thomas P. Lodise, George L. Drusano, Evan Zasowski, Amanda Dihmess, Victoria Lazariu, Leon Cosler & Louise-Anne McNutt. (2014) Vancomycin Exposure in Patients With Methicillin-Resistant Staphylococcus aureus Bloodstream Infections: How Much Is Enough?. Clinical Infectious Diseases 59:5, pages 666-675.
Crossref
Crossref
Ahmed R. Ragab, Maha K. Al-Mazroua & Mona A. Al-Harony. (2013) Incidence and Predisposing Factors of Vancomycin-Induced Nephrotoxicity in Children. Infectious Diseases and Therapy 2:1, pages 37-46.
Crossref
Crossref
S. J. van Hal, D. L. Paterson & T. P. Lodise. (2013) Systematic Review and Meta-Analysis of Vancomycin-Induced Nephrotoxicity Associated with Dosing Schedules That Maintain Troughs between 15 and 20 Milligrams per Liter. Antimicrobial Agents and Chemotherapy 57:2, pages 734-744.
Crossref
Crossref
Sepideh Elyasi, Hossein Khalili, Simin Dashti-Khavidaki & Amirhooshang Mohammadpour. (2012) Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review. European Journal of Clinical Pharmacology 68:9, pages 1243-1255.
Crossref
Crossref
Diogo Diniz Gomes Bugano, Alexandre Biasi Cavalcanti, Anderson Roman Goncalves, Claudia Salvini de Almeida & Eli?zer Silva. (2011) Cochrane meta-analysis: teicoplanin versus vancomycin for proven or suspected infection. Einstein (S?o Paulo) 9:3, pages 265-282.
Crossref
Crossref
Annie Wong-Beringer, Julianne Joo, Edmund Tse & Paul Beringer. (2011) Vancomycin-associated nephrotoxicity: a critical appraisal of risk with high-dose therapy. International Journal of Antimicrobial Agents 37:2, pages 95-101.
Crossref
Crossref
Diane M. Cappelletty. 2011. Textbook of Critical Care. Textbook of Critical Care
953
960
.
Lindsey Pritchard, Catherine Baker, James Leggett, Paul Sehdev, Allen Brown & K. Bruce Bayley. (2010) Increasing Vancomycin Serum Trough Concentrations and Incidence of Nephrotoxicity. The American Journal of Medicine 123:12, pages 1143-1149.
Crossref
Crossref
Alexandre B Cavalcanti, Anderson R Goncalves, Claudia S Almeida, Diogo DG Bugano & Eliezer Silva. (2010) Teicoplanin versus vancomycin for proven or suspected infection. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Alexandre B Cavalcanti, Anderson R Goncalves, Claudia S Almeida, Diogo B Gomes & Eliezer Silva. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
Burke A. Cunha. (2008) Vancomycin Revisited: A Reappraisal of Clinical Use. Critical Care Clinics 24:2, pages 393-420.
Crossref
Crossref
Meghan N. Jeffres, Warren Isakow, Joshua A. Doherty, Scott T. Micek & Marin H. Kollef. (2007) A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia. Clinical Therapeutics 29:6, pages 1107-1115.
Crossref
Crossref
Alan D. Tice, Susan J. Rehm, Joseph R. Dalovisio, John S. Bradley, Lawrence P. Martinelli, Donald R. Graham, R. Brooks Gainer, Mark J. KunkelRobert W. Yancey & David N. Williams. (2004) Practice Guidelines for Outpatient Parenteral Antimicrobial Therapy. Clinical Infectious Diseases 38:12, pages 1651-1671.
Crossref
Crossref
Pamela A Moise-Broder, Alan Forrest, Mary C Birmingham & Jerome J Schentag. (2004) Pharmacodynamics of Vancomycin and Other Antimicrobials in Patients with Staphylococcus aureus Lower Respiratory Tract Infections. Clinical Pharmacokinetics 43:13, pages 925-942.
Crossref
Crossref
Enrique Ginzburg, Nicholas Namias, Margaret Brown, Suzette Ball, Syed M. Hameed & Stephen M. Cohn. (2000) Gram positive infection in trauma patients: new strategies to decrease emerging Gram-positive resistance and vancomycin toxicity. International Journal of Antimicrobial Agents 16, pages 39-42.
Crossref
Crossref
N. Petit, P. Rohrbach, P. Mathieu & B. Cronier. (2000) Neutropénie à la vancomycine confirmée par une épreuve de réintroduction positive. Médecine et Maladies Infectieuses 30:10, pages 665-666.
Crossref
Crossref
Federico Pea, Donatella Poz, Massimo Baraldo & Mario Furlanut. (2000) Optimisation of Vancomycin Regimen in Neutropenic Haematological Patients with Normal Renal Function. Clinical Drug Investigation 19:3, pages 213-218.
Crossref
Crossref
Larry J. Goodman. (1999) Preventing an adverse drug event. Critical Care Medicine 27:9, pages 2027-2028.
Crossref
Crossref